JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer
Yusof, Mastura Md; Abdullah, Nik MA; Sharial, MSN Mohd; Zaatar, Adel;
  PDF(new window)
 Abstract
Background: Between October 2012 and February 2015, 25 patients with metastatic colorectal cancer (mCRC) (mean age, ) were granted access to aflibercept via the Aflibercept Named Patient Program at four centers. Materials and Methods: Here we reported the initial experience of aflibercept / FOLFIRI in combination. We evaluated treatment-related adverse events (AEs), progression-free survival (PFS) and overall survival (OS). Results: The majority of the patients experienced gastrointestinal toxicity (grade 1-2), with diarrhea (52%), mucositis (52%), and nausea/vomiting (20%) being largely observed. Neutropenia (16%) and febrile neutropenia (8%) were common grade 3-4 hematological events. Aflibercept-related toxicity was managed as per practice guidelines. No grade 5 event was reported. Median PFS was 6.12 months (95% CI, 4.80-7.20) and OS was 12 months (95% CI, 9.80-14.18). The partial response (PR), stable disease (SD), and progressive disease (PD) rates were 25% (95% CI: 23.4-27.0), 37.5% (95% CI: 31.6-43.3), and 37.5% (95% CI: 22.5-52.5), respectively. Conclusions: Aflibercept/FOLFIRI can be administered safely in a second line setting to Malaysian patients with mCRC, as the AEs experienced were generally reversible and manageable. The safety and efficacy outcomes were consistent with those observed in Western populations.
 Keywords
Aflibercept;metastatic colorectal cancer;FOLFIRI;gastrointestinal toxicity;safety;Malaysia;
 Language
English
 Cited by
1.
Antineoplastics/folinic acid, Reactions Weekly, 2017, 1642, 1, 34  crossref(new windwow)
 References
1.
Bai L, Zhang DS, Wu WJ, et al (2015). Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Med Oncol, 32, 469.

2.
Chiron M, Bagley RG, Pollard J (2014). Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther, 13, 1636-44. crossref(new window)

3.
Chiron M, Bagley RG, Pollard J, et al (2014). Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther, 13, 1636-44. crossref(new window)

4.
Common Terminology Criteria for Adverse Events v4.0 (CTCAE 2009). U.S department of health and human services.

5.
Do K, Cao L, Kang Z, et al (2015). A phase II study of sorafenib combined with cetuximab in EGFR-expressing, KRAS-mutated metastatic colorectal cancer. Clin Colorectal Cancer, 14, 154-61. crossref(new window)

6.
Garcia-Alfonso P, Ferrer A, Gil S, et al (2015). Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol, 10, 453-65. crossref(new window)

7.
Grothey A, Van Cutsem E, Sobrero A, et al (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 38, 303-12.

8.
Jitawatanarat P, Wee W (2013). Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol, 4, 231-8.

9.
Lee JJ, Chu E (2014). Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer, 13, 135-44. crossref(new window)

10.
Lim KG (2014). A review of colorectal cancer research in malaysia. Med J Malaysia, 69, 23-32.

11.
Majid N, Ghissassi I, Mrabti H, et al (2015). Bevacizumab in clinical practice. Gulf J Oncol, 1, 33-7.

12.
Malaysia cancer statistics- Data and figure (2007). National Cancer Registry Report.

13.
Muhammad S, Jiang Z, Liu Z, Kaur K, Wang X (2013). The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. J Gastrointest Oncol, 4, 72-81.

14.
Nishino M, Jagannathan JP, Ramaiya NH, et al (2010). Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgeno. 195, 281-9. crossref(new window)

15.
Norwati D, Harmy MY, Norhayati MN, Amry AR (2014). Colorectal cancer screening practices of primary care providers: results of a national survey in Malaysia. Asian Pac J Cancer Prev, 15, 2901-4. crossref(new window)

16.
Papadopoulos N, Martin J, Ruan Q (2012). Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis, 15, 171-85. crossref(new window)

17.
Passardi A, Nanni O, Tassinari D, et al (2015). Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol, 26, 1201-7. crossref(new window)

18.
Patel A, Sun W (2014). Ziv-aflibercept in metastatic colorectal cancer. Biologics, 8, 13-25.

19.
Pourhoseingholi MA (2012). Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol, 4, 68-70. crossref(new window)

20.
Product Information (2012). ZALTRAP(R) intravenous injection, ziv-aflibercept intravenous injection. sanofi-aventis U.S.LLC (per FDA), Bridgewater, NJ.

21.
Syed YY, McKeage K (2015). Aflibercept: a review in metastatic colorectal cancer. Drugs, 75, 1435-45. crossref(new window)

22.
Tang PA, Moore MJ (2013). Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and+ interpretations. Therap Adv Gastroenterol, 6, 459-73. crossref(new window)

23.
Van Cutsem E, Tabernero J, Lakomy R, et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol, 30, 3499-506. crossref(new window)

24.
Wong NA, Gonzalez D, Salto-Tellez M (2014). RAS testing of colorectal carcinoma-a guidance document from the association of clinical pathologists molecular pathology and diagnostics group. J Clin Pathol, 67, 751-7. crossref(new window)

25.
Yoshida M, Muro K, Tsuji A (2015). Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial). Eur J Cancer, 51, 935-41. crossref(new window)